As you read the financial statments for FY10 and 4th quarter, it states "Revenue decline driven by lower volumes, price reductions, and changes in business and payer mix offset by improved test mix and the number of tests per requisition."
Not a good statement. There was a loss of 1.3% in revenue for the year. The plan for FY11 is to grow 1%. Still does not capture what was lost. Interesting that the volume grew by 0.1% despite the statement made above. Doing more but getting paid less.
Since there was less revenue, the company needs to show similiar margins to keep stock holders pleased and not cause the share price to drop too much. As a result, the means to regain margin quickly is to layoff personnel. This is the same approach LabCorp employs.
Employees need to remember that these decisions are business driven, not personal. It sounds impersonal, but senior management has a fudiciary responsibility to the board and investors. No one likes this part, but it is a necessary evil.
The means to counter layoffs is for the company to grow their revenue and volumes. Other means to maintain profit margins is to reduce costs (let your mind run free on this one).
Is there one person or many persons to blame...no one knows for sure. I suspect that the clinical market is challenging and there needs to be strategic decisions to place Quest into high growth areas such as molecular diagnostics (look at Abbott and Illumina's molecular announcements...double digit growth).
Do not be surprised that there will be layoffs in struggling areas.